KCNQ2 and developmental and epileptic encephalopathy: In case 5 with KCNQ2-related Developmental and epileptic encephalopathy 7 (MIM#121200), vigabatrin was initiated based on literature-reported efficacy [23] seven days prior to standard genomic care results, but due to a lack of effect, treatment was discontinued (Fig. 3A).